Entity

Time filter

Source Type

CAMBRIDGE, United Kingdom

Grant
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2010-ITN | Award Amount: 3.23M | Year: 2010

The ITN DYNAMOL will establish a powerful new approach for the preparation of nanostructures based on dynamic covalent chemistry. This approach combines the advantages of covalent synthesis (robustness of bonds) with those of non-covalent synthesis (error correction, responsiveness) without any of the disadvantages. It therefore has the potential to provide unique solutions for several important challenges in the preparation of nanostructures that still need to be addressed. The ITN unites most European leading academic experts in the area of dynamic covalent chemistry with partners from the industrial sector. Expertise of all partners encompasses the areas of supramolecular chemistry and dynamic covalent chemistry, but individual research competences are quite diverse focussing on molecularly defined nanostructures, analysis of nanostructures, and novel applications. The complementarity and diversity thus realised is crucial for successful research and training in this area. Moreover, the two full partners from the private sector, both representing small and medium-sized enterprises, and the two associated partners, one a major chemical company, will have the critical role to bridge fundamental science with application and commercialisation of the results. The objectives of the network will be achieved by recruiting 11 early stage researchers and 1 experienced researcher. A mobility program will allow the researchers to spend time in the various laboratories of the network, thus facilitating sharing of resources and expertise. Local training at the host institutions will be supplemented by a training programme containing various elements such as biannual workshops and a summer school with the participation of experts from outside the network to realise efficient exchange of information and transfer of knowledge. The ITN thus combines world-class research with a unique education to strengthen Europes prominence in the timely field of nanoscience.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2010.2.3.3-2 | Award Amount: 21.90M | Year: 2010

RNA virus infections kill millions of humans annually, largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in this FP7 call and in response a consortium of Europes and Asias leading molecular virologists, structural biologists, medicinal chemists and bioinformaticians has been brought together to generate a state-of-the-art drug discovery and design programme. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses for which the development of drugs is considered essential (Dengue-, entero- and paramyxoviruses), whereas other relatively neglected and/or emerging RNA viruses will be explored to identify the most promising viral protein targets and antiviral compounds. A pipeline strategy has been developed to enable the inclusion in SILVER of viruses at all levels of existing knowledge. Targets for potential drugs include infectious virus, structurally characterised viral enzymes and other proteins. Leads for currently available antiviral drugs have been identified by screening compound libraries in virus-infected cell culture systems and in vitro assays using purified viral enzymes. Selective inhibitors of viral replication have also been (and are being) derived using detailed structural knowledge of viral proteins and structure-based drug design. Hits will be assayed using individual viral protein targets and replicative proteins in complex with viral RNA. The potential protective activity of the most potent inhibitors, that have a favourable (in vitro) ADME-tox profile, will be assessed in relevant infection models in animals. Licenses on promising compounds or compound classes will be presented to the interested pharmaceutical industry. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health.

Discover hidden collaborations